Overview of the AICD: From prototype to therapy of first choice

Research output: Contribution to journalArticlepeer-review


The concept of automatic implantable defibrillator, which seemed far-fetched when first proposed by Mirowski, has evolved into an effective therapeutic modality which has revolutionized treatment of patients with malignant ventricular arrhythmias. The evolution from a non-programmable, thoracotomy-based, committed device capable of treating ventricular fibrillation and rapid ventricular tachycardia to a transvenous, programmable, non-committed device incorporating antitachycardia and bradycardia pacing with extensive data logging capabilities, has extended the therapeutic applications of this treatment modality. Viewed initially as a treatment of last resort, this therapeutic approach for cardiac arrest resuscitees is now advocated by many as the 'gold standard' against which other therapies should be compared, and even as a therapy worthy of being tested for the prophylactic treatment of patients at high risk of ventricular fibrillation and ventricular tachycardia but who have not yet had an index event.

Original languageEnglish (US)
Pages (from-to)809-815
Number of pages7
JournalNew Trends in Arrhythmias
Issue number4
StatePublished - Dec 1 1991
Externally publishedYes

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Overview of the AICD: From prototype to therapy of first choice'. Together they form a unique fingerprint.

Cite this